16 completed. 16 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 16 | Completed 16 |
Follow Fungemia: new trials by email Literature Review of Fungemia trials Research Report on Fungemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation Rezafungin for Injection, Posaconazole, Fluconazole - Candidemia, Mycoses | Phase 3 | Completed | Mundipharma Research Limited | 602 | 2020-05-11 | 2026-04-13 |
| Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis Rezafungin for Injection, Caspofungin, Fluconazole - Candidemia, Mycoses | Phase 3 | Completed | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 199 | 2018-10-07 | 2023-01-06 |
| Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES) SCY-078 - Candidiasis, Invasive, Candidemia | Phase 3 | Completed | Scynexis, Inc. | 30 | 2017-11-15 | 2024-07-03 |
| Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis Anidulafungin, Fluconazole - Candidemia | Phase 3 | Completed | Pfizer | 70 | 2009-02-01 | 2019-04-04 |
| A Study to Compare Efficacy and Safety of Mycamine® and Itraconazole for Preventing Fungal Infections micafungin (Mycamine), itraconazole - Fungemia, Fungal Infections | Phase 3 | Completed | Astellas Pharma Inc | 288 | 2008-11-01 | 2016-03-28 |
| Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study Anidulafungin, Fluconazole, Voriconazole - Invasive Candidiasis | Phase 3 | Completed | Pfizer | 216 | 2008-07-01 | 2011-05-30 |
| Anidulafungin In Treatment Of Candidemia In Asian Subjects Anidulafungin - Candidemia | Phase 3 | Completed | Pfizer | 43 | 2008-01-01 | 2010-03-09 |
| Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections Isavuconazole, Caspofungin, Voriconazole - Candidiasis, Invasive, Candidemia | Phase 3 | Completed | Astellas Pharma Inc | 450 | 2007-03-08 | 2024-12-10 |
| Study of Micafungin in Patients With Invasive Candidiasis or Candidemia Micafungin, Caspofungin - Candidiasis, Candidemia | Phase 3 | Completed | Astellas Pharma Inc | 611 | 2004-09-01 | 2014-09-18 |
| Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and Candidemia Micafungin, fluconazole - Invasive Candidiasis, Candidemia | Phase 3 | Completed | Astellas Pharma Inc | 24 | 2004-08-01 | 2008-01-02 |
| The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis Anidulafungin, Fluconazole - Candidiasis | Phase 3 | Completed | Pfizer | 256 | 2003-03-01 | 2008-10-21 |
| Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia Micafungin, Liposomal Amphotericin B - Candidiasis | Phase 3 | Completed | Astellas Pharma Inc | 637 | 2003-01-01 | 2014-09-18 |
| Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections MBI 226 - Sepsis, Bacteremia | Phase 3 | Completed | BioWest Therapeutics Inc | 1400 | 2000-09-01 | 2005-09-14 |
| Voriconazole to Treat Fungal Infections Voriconazole - Mycoses | Phase 3 | Completed | National Cancer Institute (NCI) | 100 | 1999-12-01 | 2008-03-04 |
| Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients FK463, Fluconazole - Aspergillosis, Candidiasis | Phase 3 | Completed | National Cancer Institute (NCI) | 800 | 1999-11-01 | 2008-03-04 |
| An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections Voriconazole - Aspergillosis, Candidiasis | Phase 3 | Completed | National Cancer Institute (NCI) | 300 | 1999-04-01 | 2008-03-04 |
Candidemia (12) · Candidiasis, Invasive (8) · Candidiasis (7) · Mycoses (7) · Aspergillosis (3) · Sepsis (3) · Invasive Fungal Infections (2) · Pathologic Processes (2) · Systemic Inflammatory Response Syndrome (2) · Bacteremia (1) · Infections (1) · Inflammation (1) · Pneumonia, Pneumocystis (1) · Systemic candidiasis (1)
Bacterial Infections and Mycoses (16) · Pathological Conditions, Signs and Symptoms (16) · Infections (15) · Inflammation (15) · Invasive Fungal Infections (14) · Pathologic Processes (14) · Systemic Inflammatory Response Syndrome (14) · Sepsis (13) · Mycoses (9) · Candidiasis (7) · Candidiasis, Invasive (4) · Shock (2) · Bacterial Infections (1) · Lung Diseases (1)
Fluconazole (7) · Micafungin (5) · Anidulafungin (4) · Voriconazole (4) · Caspofungin (3) · Injections (2) · Rezafungin (2) · Itraconazole (1) · Trimethoprim, Sulfamethoxazole Drug Combination (1) · ibrexafungerp (1) · isavuconazole (1) · liposomal amphotericin B (1) · omiganan pentahydrochloride (1) · posaconazole (1)
Astellas Pharma Inc (5) · Pfizer (4) · National Cancer Institute (NCI) (3) · BioWest Therapeutics Inc (1) · Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Mundipharma Research Limited (1) · Scynexis, Inc. (1)
United States (12) · Canada (6) · Belgium (5) · France (5) · Germany (5) · Italy (5) · Spain (5) · India (4) · Taiwan (4) · United Kingdom (4) · Brazil (3) · China (3) · Greece (3) · Russia (3) · Switzerland (3)
David Angulo, MD (1) · Jim Pankovich (1) · Laura Cox, PhD (1) · Shan-Chwen Chang, MD (1) · Taylor Sandison, MD, MPH (1)
PMID 21147825, PMID 28459966, PMID 28597967, PMID 31280481, PMID 33438477, PMID 33891293, PMID 17568028, PMID 19804626, PMID 22469884, PMID 23676114, PMID 25902926, PMID 30289478, PMID 30418357, PMID 32032174, PMID 36442484, PMID 37773627, PMID 38008099, PMID 38502709, PMID 38985561, PMID 39259571, PMID 39468640, PMID 39529079, PMID 41194465, PMID 41940006
2008 (1), 2017 (1)